Biodistribution and dosimetry of Lu-DOTA-IBA for therapy of bone metastases.

Background: We designed and synthesized a novel bisphosphonate radiopharmaceutical ( Ga- or Lu-labeled DOTA-ibandronate [ Ga/Lu-DOTA-IBA]) for the targeted diagnosis and treatment of bone metastases. The biodistribution and internal dosimetry of a single therapeutic dose of Lu-DOTA-IBA were evaluated using a series of single-photon emission computerized tomography (SPECT) images and blood samples. Five patients with multiple bone metastases were included in this prospective study.

Efficacy and Safety of 225 Ac-DOTATATE in the Treatment of Neuroendocrine Neoplasms With High SSTR Expression.

Purpose: We aimed to evaluate the efficacy and safety of 225 Ac-DOTATATE targeted α therapy (TAT) in various neuroendocrine neoplasms (NENs) with high somatostatin receptor (SSTR) expression.

Patients And Methods: This single-center prospective study included 10 patients with histologically diagnosed NENs that exhibited increased SSTR expression on 68 Ga-DOTATATE PET/CT imaging. All patients received 225 Ac-DOTATATE TAT.

Evaluation of 188Re-DTPA-deoxyglucose as a potential cancer radiopharmaceutical.

Objective: We aimed to synthesize diethylenetriamine pentaacetic acid-deoxyglucose (DTPA-DG) radiolabeled with (188)Re and to evaluate its biologic characteristics using mammary tumor-bearing mice.

Materials And Methods: The biodistribution of the radiolabeled compound was determined by tissue counting at 3, 12, and 24 hours after injection in experimental animals. Scintigraphic examinations of nude mice bearing breast cancer (MCF-7 cells) were performed after (188)Re-DTPA-DG (18.

Noninvasive scintigraphic detection of tumor with 99mTc-DTPA-deoxyglucose: an experimental study.

Objectives: Glucosamine is a highly attractive scaffold for a glucosyl ligand, and shows activity with glucose transporters and hexokinase. In the study reported here, diethylenetriamine-pentaacetic acid-D-glucosamine (DTPA-DG) was synthesized by conjugating D-glucosamine to DTPA, and was labeled with technetium-99m ((99m)Tc). We investigated (99m)Tc-DTPA-DG for tumor detection.

Preparation and imaging research on 188Re-DTPA-deoxyglucose in MCF-7 tumor-bearing mice.

Objective: To investigate the preparation of (188)Re-diethylenetriaminepentaacetic acid-2-deoxyglucose ((188)Re-DTPA-DG) and its imaging quality and therapeutic effect.

Methods: Labeling of DTPA-DG with (188)Re was performed in the presence of stannous ion and sodium D-gluconate at a pH of 5.5 with 3 hours of incubation at 37 degrees C.